论文部分内容阅读
目的:评价Firebird支架联合替罗非班用于急性心肌梗死(AMI)中的疗效及安全性。方法:选择2011年8月至2013年8月我院收治的86例AMI患者,依据随机数字表法患者被分为:联合治疗组(50例,Firebird支架联合替罗非班)和常规治疗组(36例,裸金属支架)。对患者进行12~18个月的随访,比较两组临床疗效、临床事件发生率。结果:PCI术后,与常规治疗组比较,联合治疗组患者TIMI分级1-2级比例(13.9%比4.0%)明显减少,3~4级比例(86.1%比96.0%)明显增加,校正TIMI计帧数[(29.2±4.4)比(21.4±5.1)]明显减少,P均<0.05;术后6个月,与常规治疗组比较,联合治疗组的亚急性血栓(2.8%比0%)、心肌梗死(2.8%比0%)发生率均明显降低(P均<0.05),术后12个月,与常规治疗组比较,联合治疗组的心绞痛(16.7%比6.0%)、亚急性血栓(11.1%比0%)、心肌梗死(8.3%比0%)、心力衰竭(2.8%比0%)、再入院(11.1%比0%)发生率均明显降低(P<0.05或<0.01)。结论:Firebird支架联合替罗非班用于急性心肌梗死中的疗效显著,且安全可靠,值得推广。
Objective: To evaluate the efficacy and safety of Firebird stent combined with tirofiban in acute myocardial infarction (AMI). Methods: A total of 86 patients with AMI admitted to our hospital from August 2011 to August 2013 were randomly divided into three groups: the combination therapy group (50 patients, Firebird stent combined with tirofiban) and the conventional therapy group (36 cases, bare metal stent). The patients were followed up for 12 to 18 months. The clinical efficacy and the incidence of clinical events were compared between the two groups. Results: Compared with the conventional treatment group, the TIMI grade 1-2 grade (13.9% vs 4.0%) in the combined treatment group was significantly decreased, and the grade 3 to 4 grade (86.1% vs 96.0%) was significantly increased after PCI. The TIMI (29.2 ± 4.4) vs (21.4 ± 5.1)], P <0.05, respectively. Compared with the conventional treatment group, subacute thrombosis (2.8% vs 0%) in the combined treatment group (P <0.05). The incidence of myocardial infarction (2.8% vs 0%) was significantly lower than that of the conventional treatment group (P <0.05). Compared with the conventional treatment group, the angina pectoris (16.7% vs 6.0% (11.1% vs 0%), myocardial infarction (8.3% vs 0%), heart failure (2.8% vs 0%) and readmission (11.1% vs 0%) were significantly lower (P <0.05 or <0.01) . Conclusion: Firebird stent combined with tirofiban for acute myocardial infarction in a significant effect, and safe and reliable, it is worth promoting.